Accessibility Menu
 

Neumora Therapeutics

(NASDAQ) NMRA

Current Price$2.01
Market Cap$369.54M
Since IPO (2023)-88%
5 YearN/A
1 Year+203%
1 Month-32%

Neumora Therapeutics Financials at a Glance

Market Cap

$369.54M

Revenue (TTM)

$0.00

Net Income (TTM)

$236.93M

EPS (TTM)

$-1.45

P/E Ratio

-1.40

Dividend

$0.00

Beta (Volatility)

1.81 (High)

Price

$2.01

Volume

48,703

Open

$2.08

Previous Close

$2.01

Daily Range

$2.00 - $2.14

52-Week Range

$0.61 - $3.65

NMRA: Motley Fool Moneyball Superscore

53

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Neumora Therapeutics

Industry

Pharmaceuticals

Employees

96

CEO

Paul L. Berns

Headquarters

Watertown, DE 02472, US

NMRA Financials

Key Financial Metrics (TTM)

Gross Margin

0%

Operating Margin

0%

Net Income Margin

0%

Return on Equity

-121%

Return on Capital

-2%

Return on Assets

-1%

Earnings Yield

-71.43%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$369.54M

Shares Outstanding

182.04M

Volume

48.70K

Short Interest

0.00%

Avg. Volume

1.35M

Financials (TTM)

Gross Profit

$5.00M

Operating Income

$241.16M

EBITDA

$233.37M

Operating Cash Flow

$206.44M

Capital Expenditure

$0.00

Free Cash Flow

$206.44M

Cash & ST Invst.

$182.53M

Total Debt

$477.00K

Neumora Therapeutics Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2025YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

$369.54M

N/A

Market Cap/Employee

$3.36M

N/A

Employees

110

N/A

Net Income

$59.45M

-1.1%

EBITDA

$57.41M

+8.5%

Quarterly Fundamentals

Name
Q4 2025YOY CHG

Net Cash

$182.05M

-40.5%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$193.00K

N/A

Short Term Debt

$284.00K

-84.7%

Return on Assets

-1.24%

N/A

Return on Invested Capital

-1.52%

N/A

Free Cash Flow

$47.94M

+4.8%

Operating Cash Flow

$47.95M

+4.7%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
BCYCBicycle Therapeutics plc
$5.06+1.61%
AUTLAutolus Therapeutics plc
$1.48+0.68%
FULCFulcrum Therapeutics, Inc.
$7.90+2.20%
ADCTADC Therapeutics S.A.
$3.86+1.31%

Trending Stocks

Symbol / CompanyPricePrice Chg
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$11.54+0.07%
SNAPSnap
$5.60+0.09%
TQQQProShares Trust - ProShares UltraPro Qqq
$53.41+0.05%
IBITiShares Bitcoin Trust
$42.13+0.01%

Questions About NMRA

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.